# Defymed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/defymed

- Industry: Medical Devices & Equipment
- Headquarters: Strasbourg, France
- Website: www.defymed.com
- Total disclosed funding: $1.6M
- Latest round: Series A (Nov 5, 2013)
- Investors on record: 1

## About

Defymed is a French biotechnology company focused on developing innovative therapeutic solutions for individuals with chronic diseases, particularly through its expertise in drug delivery systems and medical device technology.Defymed specializes in creating advanced drug delivery systems designed to improve the treatment of chronic diseases. The company is headquartered in Strasbourg, France, and was acquired by Capital Grand Est in October 2015. The CEO of Defymed is Sigrist Séverine.Defymed focuses on innovative medical devices and drug delivery systems aimed at enhancing patient care in chronic disease management. Their products are designed to improve the efficacy of treatments through targeted and controlled delivery methods, catering to healthcare providers and patients globally.In 2018, Defymed reported a revenue of EUR 49,035.1, with an EBITDA of EUR -846,730.9 for the same year. The company has raised a total of EUR 1.20 mn as of the latest funding round, which was a Series A round, involving Bpifrance Investissement Régions.Defymed aims to expand its product line with new drug delivery solutions set to launch in the upcoming years. The company is targeting expansion into additional European markets and possibly North America by 2025. The recent funding round will be utilized to support these product developments and market entry strategies.

## Funding rounds

- Series A, Nov 5, 2013, $1.6M — Bpifrance Investissement Régions

## Investors

- Bpifrance Investissement Régions (https://capitalatlas.ai/funds/bpifrance-investissement-regions) — Series A